Conference Coverage
Conference Coverage
Lurbinectedin shows activity against relapsed Ewing’s
CHICAGO – The agent blocks DNA transcription and induces double-strand breaks leading to apoptosis; results warrant further exploration,...
Conference Coverage
Adjuvant chemotherapy benefits high-risk sarcoma patients
Chemotherapy halved the risk of disease progression and death for patients with low probability of 10-year overall survival.
Conference Coverage
Rapid drug alteration a bust in metastatic GIST
Short alternating cycles of sunitinib with regorafenib failed to reach active drug levels in patients with heavily pretreated disease.
Conference Coverage
ctDNA profiles pre- and posttreatment KIT mutations in GIST
CHICAGO – A broad spectrum KIT inhibitor should be a part of post-imatinib therapy for GIST, data from a phase 1 study suggest.
Conference Coverage
Novel TKI PLX9486 showed efficacy against KIT mutations in GIST
CHICAGO – Combined with another investigational tyrosine kinase inhibitor, the compound showed activity against a broad range of resistance...
Conference Coverage
Low response rate with trofosfamide for advanced STS in elderly
CHICAGO – Of 80 patients with previously untreated metastatic soft-tissue sarcomas, 2 had complete, durable responses to oral trofosfamide.
News
Trabectedin bests supportive care in advanced soft-tissue sarcomas
CHICAGO – The benefit of trabectedin vs. best supportive care was entirely in patients with leiomyosarcoma or liposarcoma.
Conference Coverage
Neoadjuvant-treated N2 rectal cancer linked to PCR failure
ORLANDO – Is a watch-and-wait protocol appropriate for pretreated N2 rectal cancer patients?
Conference Coverage
Phase 2 trial: Dendritic cell vaccine maintenance prolongs PFS in EOC
DCVAC maintenance after chemotherapy prolonged progression-free survival by almost 6 months in EOC patients who have undergone primary debulking...
Conference Coverage
Higher lymph node harvest could improve right-side colon cancer outcomes
ORLANDO – Recent studies have demonstrated worse outcomes for right-sided versus left-sided colon cancers.
Conference Coverage
Lower CTC count IDs indolent MBC disease subset
A CTC count less than 5 per 7.5 mL of blood in MBC patients indicates an indolent disease subset, pooled data from two large cohorts show.